Table 1.

Gal-8 and -9 staining correlated with clinical and pathological data.

	Gal-8 Expression (Cytoplasm)		p-Value	Gal-8 Expression (Nucleus)		p-Value	Gal-9 Expression (Cytoplasm)			p-Value
	Low	High		Negative	Positive		Negative	Moderate	High
Histology
Serous	40	62	NS	54	48	NS	24	71	9	0.024
Clear cell	2	9		3	8		1	10	0
Endometrioid	2	17		8	11		6	10	5
Mucinous	3	8		5	7		1	6	4
Tumor Stage
pT1	10	26	NS	14	23	NS	8	20	9	0.018
pT2+	37	69		55	51		24	77	8
Lymph node
pN0/ pNX	25	70	0.019	43	53	NS	26	61	12	NS
pN1	22	26		27	21		6	36	6
Distant Metastasis
pM0/pMX	45	94	NS	68	72	NS	32	92	17	NS
pM1	2	2		2	2		0	5	1
Grading
G1	7	26	NS	13	21	NS	7	19	8	0.006
G2+	37	62		53	46		24	72	5
FIGO
I/ II	8	33	0.033	14	28	0.011	6	25	11	0.002
III/ IV	37	60		55	42		25	69	6
Age
≤60 years	24	51	NS	32	43	NS	10	52	17	<0.001
>60 years	23	45		38	31		22	45	1

TNM staging was accomplished according to the Union for International Cancer Control (UICC); pT1 = tumor stage 1; pT2+ = tumor stage 2 or higher; pN0 = lymph node stage 0; pNX = lymph node stage not evaluated; pN1 = lymph node stage 1; pM0 = distant metastasis stage 0; pMX = distant metastasis not evaluated; pM1 = distant metastasis stage 1; G1 = grade 1; G2+ = grade 2 or higher; NS = Not significant (p > 0.05).